微芯生物(688321) - 2024 Q1 - 季度财报

Revenue and Profitability - Revenue for the reporting period was RMB 130,604,180.46, representing a year-on-year increase of 22.60%[9] - Total operating revenue for Q1 2024 reached RMB 130,604,180.46, a 22.60% increase compared to the same period last year, driven by the growth in sales revenue of Chiglitazar Sodium[21][32] - Net profit attributable to shareholders of the listed company was RMB -18,304,645.53, indicating a loss[9] - Net profit for Q1 2024 was a loss of RMB -18,304,645.53, compared to a loss of RMB -35,783,904.58 in the same period last year[44] - Net profit attributable to shareholders of the listed company narrowed its loss by 43.63% year-over-year[24] - Basic earnings per share (EPS) was RMB -0.0448, reflecting a loss per share[9] Cash Flow and Investments - Net cash flow from operating activities was RMB 35,428,190.17, a significant improvement compared to the negative RMB -48,582,917.14 in the same period last year[9][16] - Cash received from investments was RMB 463,900,500.00, a significant increase from RMB 290,000,000.00 in the previous year[16] - Cash paid for investments was RMB 395,814,500.00, up from RMB 247,000,000.00 in the same period last year[16] - Net cash flow from financing activities was RMB 33,413,741.14, a decrease from RMB 159,495,539.79 in the previous year[16] - Cash and cash equivalents increased to RMB 467,877,634.95 as of March 31, 2024, up from RMB 375,437,648.61 at the end of 2023[20] - Cash and cash equivalents increased by RMB 94,475,089.34 in Q1 2024, with an ending balance of RMB 361,164,427.90[47] - Cash received from sales of goods and services increased significantly from 113,252,890.19 RMB to 207,095,989.01 RMB[52] Assets and Liabilities - Total assets as of March 31, 2024, amounted to RMB 3,213,475,496.86, a slight increase of 0.32% compared to the end of the previous year[32] - Total assets increased slightly from 3,203,249,429.12 RMB to 3,213,475,496.86 RMB[50] - Total liabilities as of March 31, 2024, were RMB 1,524,025,405.30, a slight increase from RMB 1,493,353,557.17 at the end of 2023[28] - Long-term loans increased to RMB 551,185,753.30, up from RMB 490,728,419.96 at the end of 2023[28] - Short-term borrowings decreased from 130,112,786.24 RMB to 111,092,757.07 RMB[50] - Accounts payable decreased from 8,975,080.04 RMB to 3,511,882.09 RMB[50] - Contract liabilities increased from 79,952.88 RMB to 742,648.52 RMB[50] - Deferred tax assets decreased from 2,082,893.55 RMB to 1,274,224.61 RMB[50] - Other non-current assets increased from 27,905,628.87 RMB to 37,898,788.36 RMB[50] - Fixed assets decreased from 692,222,974.82 RMB to 688,533,005.22 RMB[50] - Development expenditure increased from 398,561,645.92 RMB to 426,261,234.82 RMB[50] - Total non-current assets increased from 2,073,162,574.58 RMB to 2,109,399,387.15 RMB[50] Shareholders and Equity - The number of ordinary shareholders at the end of the reporting period was 21,150[25] - Boao Biotechnology Group holds 8.44% of the company's shares, totaling 34,705,162 shares[37] - Shenzhen Haideman Biotech Development Co., Ltd. holds 5.58% of the company's shares, totaling 22,936,008 shares[37] - LU XIANPING, an overseas individual, holds 5.41% of the company's shares, totaling 22,239,625 shares[37] - Shenzhen Haideruibo Investment Co., Ltd. holds 4.82% of the company's shares, totaling 19,817,445 shares[37] - Shenzhen Haidekangcheng Investment Partnership holds 3.72% of the company's shares, totaling 15,285,290 shares[37] - Vertex Technology Fund (III) Ltd holds 3.19% of the company's shares, totaling 13,125,918 shares[37] - Shenzhen Haidekangcheng Investment Partnership participated in the securities lending business, lending 130,000 shares to CITIC Securities for market-making activities[48] R&D and Operating Costs - R&D investment for Q1 2024 was RMB 80,200,838.60, accounting for 61.41% of the operating revenue, a decrease of 19.31 percentage points compared to the previous year[32] - Total operating costs for Q1 2024 were RMB 148,782,922.18, with sales expenses accounting for RMB 55,974,005.61 and R&D expenses at RMB 52,501,249.70[44] Comprehensive Income and Other Items - Comprehensive income attributable to owners of the parent company was RMB -18,191,945.95, compared to RMB -33,435,826.06 in the same period last year[3] - Foreign currency translation differences contributed RMB 112,699.58 to other comprehensive income, compared to a loss of RMB -958,990.66 in the previous year[3] - Non-recurring gains and losses amounted to RMB 3,671,431.72, including government subsidies of RMB 3,355,129.71[6][11] - Sales volume of Chiglitazar Sodium surged by 665.80% year-over-year, with sales revenue increasing by 3,126.77%[24]